Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091611 · ClinicalTrials.gov registry record · Phase 1
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00091611: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00091611 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091611, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Background: * Some patients with advanced kidney cancer have immune cells that can recognize and kill their cancer, but the cells are not active enough or numerous enough to accomplish this on their own. * In recent studies of patients with advanced melanoma, some patients given special tumor-fighting cells (cells taken from the patient's tumor cells and grown in the laboratory) showed some anti-tumor response. Objectives: -To determine whether special tumor-fighting cells taken from the patient's blood or tumor and grown in the laboratory can cause tumors in patients with kidney cancer to shrink when they are given back to the patient along with interleukin-2. Eligibility: Patients 18 years of age or older with advanced kidney cancer. Design: * Up to 29 patients will be treated in this study. * Patients undergo tumor biopsy to collect tumor cells for creating special tumor-fighting cells for later infusion. * Patients undergo apheresis to collect stem cells for later re-infusion. For apheresis, whole blood is collected through a needle in an arm vein and circulated through a cell-separating machine where the stem cells are extracted. The rest of the blood is returned through the same needle or a needle in the other arm. * Before receiving the treated white cells, patients are given two drugs to suppress the immune system so the treated cells can work without interference from immune system cells. They are given cyclophosphamide over 2 days through a catheter (plastic tube inserted into a vein in the arm or neck) and fludarabine through the catheter over 15-30 minutes for the next 5 days. * The day after the last dose of fludarabine, the tumor-fighting cells are infused through a vein over 10-20 minutes. * Following the cell infusion, patients start treatment with high-dose interleukin-2 every 8 hours for a maximum of 12 doses. * Patients are evaluated with x-ray studies about 1 month after receiving the cells and interleukin 2 (IL-2) to look for tumor respons
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mesna
- DRUG OKT3
- DRUG IL-2 (interleukin-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Why NCT00091611 stopped before completion
NCT00091611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00091611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091611 about?
NCT00091611 is a clinical study titled "Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer". Background: * Some patients with advanced kidney cancer have immune cells that can recognize and kill their cancer, but the cells are not active enough or numerous enough to accomplish this on their own. * In recent studies of patients with advanced melanoma, some patients given special tumor-fight...
What is the current status of trial NCT00091611?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2004-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00091611?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mesna (DRUG), OKT3 (DRUG), IL-2 (interleukin-2) (DRUG).
Who is sponsoring clinical trial NCT00091611?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091611's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia